Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;10(Suppl 33):S4065-S4068.
doi: 10.21037/jtd.2018.09.83.

"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?

Alessia Spagnuolo  1 , Cesare Gridelli  1
Affiliations
Editorial

"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?

Alessia Spagnuolo et al. J Thorac Dis. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: C Gridelli received honoraria as speaker bureau and advisory board member for BMS, MSD, Astra Zeneca. A Spagnuolo has no conflicts of interest to declare.

Comment on

References

    1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12. 10.1016/j.coi.2011.12.009 - DOI - PMC - PubMed
    1. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7. 10.1038/nature04444 - DOI - PubMed
    1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. 10.1016/j.immuni.2013.07.012 - DOI - PubMed
    1. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017;28:2377-85. 10.1093/annonc/mdx286 - DOI - PubMed
    1. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139-48. 10.1016/j.ejca.2015.11.016 - DOI - PubMed